
Opinion|Videos|October 4, 2024
Introducing Bispecifics for Extensive-Stage SCLC
Panelists discuss how tarlatamab, a bispecific T-cell engager therapy, received accelerated approval for extensive-stage small cell lung cancer (SCLC) in May 2024, examining its mechanism of action, pivotal clinical data, management of adverse events, practical considerations for administration, and its position within the SCLC treatment algorithm.
Advertisement
Episodes in this series

Tarlatamab was given accelerated approval in May 2024 for extensive-stage small cell lung cancer (SCLC). How does this therapy work, and what was the important data the led to its approval?
- What are the main adverse events to watch for, and do you manage them?
- Are there any other clinical considerations, such as inpatient or outpatient dosing, when using a bispecific T-cell engager like tarlatamab?
- Where does this therapy fit into your treatment algorithm for patients with SCLC?
Advertisement
Related to this article

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5

